Comparing treatments to stop bleeding in patients: A clinical study of local bleeding control methods

Comparative study of local haemostatic agent on hemorrhagic patients (clinical study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN19155058

Enrollment

Registered

2025-05-29

Start date

2022-11-16

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preventing the risk of bleeding in patients taking the anticoagulants aspirin and warfarin Oral Health

Interventions

A clinical study was conducted on 40 patients, divided into two groups based on the type of anticoagulant used (aspirin or warfarin). Each patient received treatment with different hemostatic dressing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age between 40 and 75 years. 2. Patients use aspirin at a daily dose of 80 mg or oral warfarin. 3. Patients using warfarin must have a stable INR value within the therapeutic range (2-3.5) [23]. 4. Obtaining written informed consent from all participants, with their commitment to maintaining the anticoagulant doses unchanged throughout the study period. 5. Requirement for simple tooth extractions of paired teeth, without the need for complex surgical intervention.

Exclusion criteria

Exclusion criteria: 1. Presence of uncontrolled systemic diseases that contraindicate tooth extraction. 2. Participation in other clinical trials during the study period is necessary to avoid treatment overlap and influence on results. 3. Unstable INR, where patients with fluctuations in INR outside the required therapeutic range (2-3.5) before extraction or during follow-up were excluded. 4. Severe alcohol or tobacco dependence due to their negative effects on wound healing post-extraction

Design outcomes

Primary

Measure	Time frame
1. Bleeding severity is measured using the VIBe scale at baseline, day 3, and day 7 2. Gingival healing is measured using the Gingival Healing Index (GHI) at day 3 and day 7 3. Pain intensity is measured using the Visual Analogue Scale (VAS) at baseline, day 3, and day 7 4. Late bleeding occurrence is measured using clinical observation at 24 hours after extraction	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

India, Iran, Iraq, Jordan, Kuwait, Lebanon, Morocco, Syria

Contacts

Public ContactWalaa ALSULIMAN

Walaaalsuliman2@gmail.com-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026